FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1556943798> ?p ?o ?g. }

• W1556943798 abstract "Background Inhaled corticosteroids (ICS) are the cornerstone of asthma maintenance treatment in children. Particularly among parents, there is concern about the safety of ICS as studies in children have shown reduced growth. Small‐particle‐size ICS targeting the smaller airways have improved lung deposition and effective asthma control might be achieved at lower daily doses. Ciclesonide is a relatively new ICS. This small‐particle ICS is a pro‐drug that is converted in the airways to an active metabolite and therefore with potentially less local (throat infection) and systemic (reduced growth) side effects. It can be inhaled once daily, thereby possibly improving adherence. Objectives To assess the efficacy and adverse effects of ciclesonide compared to other ICS in the management of chronic asthma in children. Search methods We searched the Cochrane Airways Group Register of trials with pre‐defined terms. Additional searches of MEDLINE (via PubMed), EMBASE and Clinicalstudyresults.org were undertaken. Searches are up to date to 7 November 2012. Selection criteria Randomised controlled parallel or cross‐over studies were eligible for the review. We included studies comparing ciclesonide with other corticosteroids both at nominally equivalent doses or lower doses of ciclesonide. Data collection and analysis Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. Main results Six studies were included in this review (3256 children, 4 to 17 years of age). Two studies were published as conference abstracts only. Ciclesonide was compared to budesonide and fluticasone. Ciclesonide compared to budesonide (dose ratio 1:2): asthma symptoms and adverse effect were similar in both groups. Pooled results showed no significant difference in children who experience an exacerbation (risk ratio (RR) 2.20, 95% confidence interval (CI) 0.75 to 6.43). Both studies reported that 24‐hour urine cortisol levels showed a statistically significant decrease in the budesonide group compared to the ciclesonide group. Ciclesonide compared to fluticasone (dose ratio 1:1): no significant differences were found for the outcome asthma symptoms. Pooled results showed no significant differences in number of patients with exacerbations (RR 1.37, 95% CI 0.58 to 3.21) and data from a study that could not be pooled in the meta‐analysis reported similar numbers of patients with exacerbations in both groups. None of the studies found a difference in adverse effects. No significant difference was found for 24‐hour urine cortisol levels between the groups (mean difference 0.54 nmol/mmol, 95% CI ‐5.92 to 7.00). Ciclesonide versus fluticasone (dose ratio 1:2) was assessed in one study and showed similar results between the two corticosteroids for asthma symptoms. The number of children with exacerbations was significantly higher in the ciclesonide group (RR 3.57, 95% CI 1.35 to 9.47). No significant differences were found in adverse effects (RR 0.98, 95% CI 0.81 to 1.14) and 24‐hour urine cortisol levels (mean difference 1.15 nmol/mmol, 95% CI 0.07 to 2.23). The quality of evidence was judged 'low' for the outcomes asthma symptoms and adverse events and 'very low' for the outcome exacerbations for ciclesonide versus budesonide (dose ratio 1:1). The quality of evidence was graded 'moderate' for the outcome asthma symptoms, 'very low' for the outcome exacerbations and 'low' for the outcome adverse events for ciclesonide versus fluticasone (dose ratio 1:1). For ciclesonide versus fluticasone (dose ratio 1:2) the quality was rated 'low' for the outcome asthma symptoms and 'very low' for exacerbations and adverse events (dose ratio 1:2). Authors' conclusions An improvement in asthma symptoms, exacerbations and side effects of ciclesonide versus budesonide and fluticasone could be neither demonstrated nor refuted and the trade‐off between benefits and harms of using ciclesonide instead of budesonide or fluticasone is unclear. The resource use or costs of different ICS should therefore also be considered in final decision making. Longer‐term superiority trials are needed to identify the usefulness and safety of ciclesonide compared to other ICS. Additionally these studies should be powered for patient relevant outcomes (exacerbations, asthma symptoms, quality of life and side effects). There is a need for studies comparing ciclesonide once daily with other ICS twice daily to assess the advantages of ciclesonide being a pro‐drug that can be administered once daily with possibly increased adherence leading to increased control of asthma and fewer side effects." @default.
• W1556943798 created "2016-06-24" @default.
• W1556943798 creator A5028188792 @default.
• W1556943798 creator A5032291587 @default.
• W1556943798 creator A5053890035 @default.
• W1556943798 creator A5084495124 @default.
• W1556943798 date "2013-02-28" @default.
• W1556943798 modified "2023-09-28" @default.
• W1556943798 title "Ciclesonide versus other inhaled corticosteroids for chronic asthma in children" @default.
• W1556943798 cites W1549564082 @default.
• W1556943798 cites W1644069869 @default.
• W1556943798 cites W1772071424 @default.
• W1556943798 cites W1903824044 @default.
• W1556943798 cites W1963763550 @default.
• W1556943798 cites W1970777902 @default.
• W1556943798 cites W1971724725 @default.
• W1556943798 cites W1975932764 @default.
• W1556943798 cites W1984247088 @default.
• W1556943798 cites W1984949637 @default.
• W1556943798 cites W1985579704 @default.
• W1556943798 cites W1988683995 @default.
• W1556943798 cites W1992297329 @default.
• W1556943798 cites W2002203685 @default.
• W1556943798 cites W2003429279 @default.
• W1556943798 cites W2011267749 @default.
• W1556943798 cites W2013137769 @default.
• W1556943798 cites W2019445870 @default.
• W1556943798 cites W2024458062 @default.
• W1556943798 cites W2026180619 @default.
• W1556943798 cites W2029321506 @default.
• W1556943798 cites W2031556085 @default.
• W1556943798 cites W2033792259 @default.
• W1556943798 cites W2036904276 @default.
• W1556943798 cites W2043990114 @default.
• W1556943798 cites W2063548445 @default.
• W1556943798 cites W2071865603 @default.
• W1556943798 cites W2082466693 @default.
• W1556943798 cites W2085277727 @default.
• W1556943798 cites W2107637612 @default.
• W1556943798 cites W2110789029 @default.
• W1556943798 cites W2111766384 @default.
• W1556943798 cites W2117867745 @default.
• W1556943798 cites W2118957675 @default.
• W1556943798 cites W2123078357 @default.
• W1556943798 cites W2129161565 @default.
• W1556943798 cites W2130082216 @default.
• W1556943798 cites W2134581138 @default.
• W1556943798 cites W2139707654 @default.
• W1556943798 cites W2150944749 @default.
• W1556943798 cites W2152587755 @default.
• W1556943798 cites W2155441883 @default.
• W1556943798 cites W2157232528 @default.
• W1556943798 cites W2168690503 @default.
• W1556943798 cites W4236639597 @default.
• W1556943798 cites W4244631877 @default.
• W1556943798 doi "https://doi.org/10.1002/14651858.cd010352" @default.
• W1556943798 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23450613" @default.
• W1556943798 hasPublicationYear "2013" @default.
• W1556943798 type Work @default.
• W1556943798 sameAs 1556943798 @default.
• W1556943798 citedByCount "22" @default.
• W1556943798 countsByYear W15569437982013 @default.
• W1556943798 countsByYear W15569437982014 @default.
• W1556943798 countsByYear W15569437982015 @default.
• W1556943798 countsByYear W15569437982016 @default.
• W1556943798 countsByYear W15569437982017 @default.
• W1556943798 countsByYear W15569437982018 @default.
• W1556943798 countsByYear W15569437982019 @default.
• W1556943798 countsByYear W15569437982020 @default.
• W1556943798 countsByYear W15569437982021 @default.
• W1556943798 countsByYear W15569437982022 @default.
• W1556943798 crossrefType "journal-article" @default.
• W1556943798 hasAuthorship W1556943798A5028188792 @default.
• W1556943798 hasAuthorship W1556943798A5032291587 @default.
• W1556943798 hasAuthorship W1556943798A5053890035 @default.
• W1556943798 hasAuthorship W1556943798A5084495124 @default.
• W1556943798 hasBestOaLocation W15569437982 @default.
• W1556943798 hasConcept C126322002 @default.
• W1556943798 hasConcept C197934379 @default.
• W1556943798 hasConcept C2776042228 @default.
• W1556943798 hasConcept C2776136866 @default.
• W1556943798 hasConcept C2777588912 @default.
• W1556943798 hasConcept C2779028295 @default.
• W1556943798 hasConcept C2781212218 @default.
• W1556943798 hasConcept C2991922776 @default.
• W1556943798 hasConcept C71924100 @default.
• W1556943798 hasConceptScore W1556943798C126322002 @default.
• W1556943798 hasConceptScore W1556943798C197934379 @default.
• W1556943798 hasConceptScore W1556943798C2776042228 @default.
• W1556943798 hasConceptScore W1556943798C2776136866 @default.
• W1556943798 hasConceptScore W1556943798C2777588912 @default.
• W1556943798 hasConceptScore W1556943798C2779028295 @default.
• W1556943798 hasConceptScore W1556943798C2781212218 @default.
• W1556943798 hasConceptScore W1556943798C2991922776 @default.
• W1556943798 hasConceptScore W1556943798C71924100 @default.
• W1556943798 hasLocation W15569437981 @default.
• W1556943798 hasLocation W15569437982 @default.
• W1556943798 hasLocation W15569437983 @default.
• W1556943798 hasLocation W15569437984 @default.
• W1556943798 hasOpenAccess W1556943798 @default.

• next